Ebrahim Versi - 15 Sep 2023 Form 4 Insider Report for DMK PHARMACEUTICALS Corp

Reporting relationship: CEO, Director
Issuer ticker: N/A
Reported as of: 15 Sep 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Sep 2023, 17:17:24 UTC
Prior SEC filing: 30 May 2023
Source filing: View source filing
Reporting owner signature: /s/ David J. Marguglio, as Attorney-in-Fact for Ebrahim Versi

Key filing fact

Ebrahim Versi filed Form 4 for DMK PHARMACEUTICALS Corp on 19 Sep 2023.

Key facts

This page summarizes Ebrahim Versi's Form 4 filing for DMK PHARMACEUTICALS Corp.
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 19 Sep 2023, 17:17.

Change

Previous filing in this sequence was filed on 30 May 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ADMP transaction

Common Stock

Conversion of derivative security

Transaction value: $0
Shares: +729,200
Change %: +412%
Price: $0.000000
Shares after: 906,394
Date: 15 Sep 2023
Ownership: By Versi Group LLC
Footnotes: F1, F2

ADMP holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 8,745
Date: 15 Sep 2023
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ADMP transaction Derivative

Series E Convertible Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -729
Change %: -38%
Price: $0.000000
Shares after: 1,212
Date: 15 Sep 2023
Ownership: By Versi Group LLC
Underlying class: Common Stock
Underlying amount: 729,200
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

On September 15, 2023, Versi Group, LLC converted 729.2 shares of Series E Convertible Preferred Stock ("Series E Preferred") into 729,200 shares of Common Stock, pursuant to the terms of the Series E Preferred. Each share of Series E Preferred is convertible into 1,000 shares of Common Stock at the election of the reporting person, subject to certain beneficial ownership limitations. The Series E Preferred has no expiration date.

Footnote F2

The reported shares are owned directly by Versi Group, LLC, of which the reporting person is the manager and a member. The reporting person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interests therein.